Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag

Table 6

COX univariate analysis.

Features		SE	Wald	Df
Gender	-1.135	0.7157	2.514	1	0.1128	0.3214
Age	1.891	1.004	3.551	1	0.0595	6.629
Smoking history	-0.5602	0.7181	0.6085	1	0.4353	0.5711
TNM stage	3.812	1.175	10.53	1	0.0012	45.25
Number of tumors	1.320	0.9133	2.089	1	0.1483	3.744
Line of medication	2.122	0.9933	4.566	1	0.0326	8.352
Histology types	0.7421	1.000	0.5511	1	0.4579	2.101